NCT03020082 - Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

Chronic Hepatitis C

Interventions

DRUG

Danoprevir

Danoprevir (DNV)administered orally 100mg BID for 12 weeks;

DRUG

Ritonavir

Ritonavir administered orally 100mg BID for 12 weeks;

DRUG

peginterferon alfa-2a

PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;

DRUG

RBV

RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.